An immunological biomarker to predict MTX response in early RA

Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and

(2012) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

(2010) B. Saleem et al.   ANNALS OF THE RHEUMATIC DISEASES

Predictors for remission in rheumatoid arthritis patients: A systematic review

(2010) Wanruchada Katchamart et al.   ARTHRITIS CARE & RESEARCH

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET

Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse

(2007) C H Burgoyne et al.   ANNALS OF THE RHEUMATIC DISEASES